治疗复发难治性多发性骨髓瘤新药:selinexor  

A new drug in treating relapsed or refractory multiple myeloma: selinexor

作　　者：张芳[1] 闫泰山[1] 赵艳[1] ZHANG Fang;YAN Tai-shan;ZHAO Yan(Department of Pharmacy,Qingdao Municipal Hospital,Qingdao SHANDONG 266011,China)

机构地区：[1]青岛市市立医院药学部,山东青岛266011

出　　处：《中国新药与临床杂志》2020年第5期277-280,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：selinexor是首个获批上市的核输出蛋白1(XPO1)抑制剂,可通过特异性抑制XPO1,减少核内Rb、p53、p21等肿瘤抑制蛋白输出,从而达到抗肿瘤的目的。2019年7月3日,美国食品和药物管理局批准selinexor与地塞米松联合应用于成年复发难治性多发性骨髓瘤患者的治疗。患者需既往接受过至少四种系统性治疗,且对至少两种蛋白酶体抑制剂、两种免疫调节剂和抗CD38单克隆抗体耐药。selinexor的主要不良反应包括血小板减少、疲劳、胃肠道反应、贫血和低钠血症等。Selinexor is the first approved nuclear export protein 1(XPO1) inhibitor, which can specifically inhibit XPO1 and reduce the export of tumor suppressor proteins such as Rb, p53 and p21 in the nucleus, thus achieving the goal of anti-tumor. It was approved combinated with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who had received at least four prior therapies and whose disease was refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody by the U.S. Food and Drug Administration on July 3, 2019. The main adverse reactions of selinexor include thrombocytopenia, fatigue, gastrointestinal toxicity, anemia, hyponatremia and so on.

关 键 词：selinexor 多发性骨髓瘤 抗肿瘤药 核输出蛋白抑制剂 

分 类 号：R733.3[医药卫生—肿瘤] R979.1[医药卫生—临床医学]